These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 8809817)

  • 1. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?
    Mouatt-Prigent A; Karlsson JO; Agid Y; Hirsch EC
    Neuroscience; 1996 Aug; 73(4):979-87. PubMed ID: 8809817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?
    Mouatt-Prigent A; Agid Y; Hirsch EC
    Brain Res; 1994 Dec; 668(1-2):62-70. PubMed ID: 7704619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
    Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
    Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microtopography of D1 dopaminergic binding sites in the human substantia nigra: an autoradiographic study.
    Thibaut F; Hirsch EC; Raisman R; Javoy-Agid F; Agid Y
    Neuroscience; 1990; 37(2):387-98. PubMed ID: 1983469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.
    McRitchie DA; Cartwright HR; Halliday GM
    Exp Neurol; 1997 Mar; 144(1):202-13. PubMed ID: 9126172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease.
    Kastner A; Hirsch EC; Herrero MT; Javoy-Agid F; Agid Y
    J Neurochem; 1993 Sep; 61(3):1024-34. PubMed ID: 8103078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mice.
    Gaspar P; Ben Jelloun N; Febvret A
    Neuroscience; 1994 Jul; 61(2):293-305. PubMed ID: 7969910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal vulnerability in Parkinson's disease.
    Hirsch EC; Faucheux B; Damier P; Mouatt-Prigent A; Agid Y
    J Neural Transm Suppl; 1997; 50():79-88. PubMed ID: 9120427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does oxidative stress participate in nerve cell death in Parkinson's disease?
    Hirsch EC
    Eur Neurol; 1993; 33 Suppl 1():52-9. PubMed ID: 8375433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calpastatin immunoreactivity in the monkey and human brain of control subjects and patients with Parkinson's disease.
    Mouatt-Prigent A; Karlsson JO; Yelnik J; Agid Y; Hirsch EC
    J Comp Neurol; 2000 Apr; 419(2):175-92. PubMed ID: 10722997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
    Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
    Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
    Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
    Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
    Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
    Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
    Hartmann A; Michel PP; Troadec JD; Mouatt-Prigent A; Faucheux BA; Ruberg M; Agid Y; Hirsch EC
    J Neurochem; 2001 Mar; 76(6):1785-93. PubMed ID: 11259496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
    Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
    Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catecholaminergic systems in the medulla oblongata in parkinsonian syndromes: a quantitative immunohistochemical study in Parkinson's disease, progressive supranuclear palsy, and striatonigral degeneration.
    Malessa S; Hirsch EC; Cervera P; Duyckaerts C; Agid Y
    Neurology; 1990 Nov; 40(11):1739-43. PubMed ID: 1978260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
    Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease.
    Hirsch EC; Graybiel AM; Agid Y
    Acta Neurol Scand Suppl; 1989; 126():19-22. PubMed ID: 2575832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.